Phase 1b dexamethasone (glucocorticoid) plus venetoclax trial in treatment-naïve AML.

This investigator-initiated single-arm study at the University of Vermont evaluates the safety and tolerability of adding dexamethasone to venetoclax-based low-intensity therapy in adult AML patients ineligible for intensive chemotherapy, with up to six 28-day cycles and assessments of patient-reported outcomes and early treatment responses.